HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Pyxis Oncology (NASDAQ:PYXS) and maintained a $7 price target.

April 10, 2024 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Pyxis Oncology with a $7 price target.
Reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co. typically signals confidence in the company's future performance, potentially leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100